- About About
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor Which conditions qualify? The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
- News News
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Reports 2020 State of the States Medical Cannabis Access for Pain Treatment Medical Cannabis in America Recognizing Science using the Data Quality Act Fact Sheet on ASA's Data Quality Act Petition to HHS Data Quality Act Briefs ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit
- Join Join
Today, the U.S. House of Representatives passed the Marijuana Opportunity Reinvestment and Expungement Act (MORE Act), or HR 3884, which was introduced by Congressman Jerrold Nadler (D-NY) on July 23, 2019. The vote was historic, with the House voting for the first time to approve legislation to remove cannabis from Schedule I of the U.S. Controlled Substances Act.
Americans for Safe Access (ASA) worked closely with Congressman Lou Correa’s (D-CA) office to secure language in the measure as it was brought to the House floor that authorizes research on the mental and physical health applications of cannabis to veterans. “ASA would like to thank Congressman Correa who has been a strong champion of veterans cannabis research, authoring HR 712, the VA Medical Cannabis Research Act of 2019, which was the basis of the amendment,” said Dustin McDonald, interim policy director of Americans for Safe Access.
Americans for Safe Access (ASA) and its members have worked tirelessly over the past 18 years to pass laws at the federal level for the benefit of medical cannabis patients. “The MORE Act is a signal to medical cannabis patients that their voices have finally been heard at the national level in Congress,” said Debbie Churgai, executive director of Americans for Safe Access.
The MORE Act would greatly benefit medical cannabis patients in many ways. By decriminalizing cannabis at the federal level, the bill would:
- Enable patients to travel across state lines with their medication without fear of punitive law enforcement intervention, fines, or jail time.
- Introduce much-needed federal leadership and oversight over key components of medical cannabis policy that states have struggled with, such as laboratory testing and labeling standards, patient access, and medical cannabis businesses practices.
- Facilitate federal, academic, and private research on medical cannabis in the U.S.
- End the conflict of laws between the federal and state governments on cannabis.
“Today, in the U.S., there are nearly 5 million registered cannabis patients. These patients, and the millions of non-registered adult-use patients, have been denied safe and legal access to medicine they need to treat their health conditions for 50 years because of the federal government’s placement of cannabis under Schedule I of the Controlled Substances Act (CSA).
"As a patient-focused organization, ASA has not just supported the MORE Act, but also worked with legislators to make it more beneficial for patients, and we are happy to see that it passed in the House. We hope to build on this landmark action until all the needs of medical cannabis patients are met at the federal level,” said Churgai.
Regarding next steps, House passage of the MORE Act sets the stage for Senate consideration of the bill. However, it is unlikely that the chamber will take the measure up before Congress wraps up work for the year, forcing sponsors to reintroduce the bill in the 117th session of Congress that begins in January. “Between now and then, ASA will aim to work with bill sponsors to fine tune the legislation for consideration in the new Congress,” said Churgai.